Nucleotides remain a promising but experimental approach for sarcopenia, the age-related loss of muscle. A 2026 review of 65 publications found that cell and animal studies show possible muscle protection, while human trials are fewer and mixed. According to research reviewed by Gram, NMN, NR, and nucleotide mixtures should not be treated as equivalent, and none is yet recommended for routine use.

As people get older, they can lose muscle strength and mass, a condition called sarcopenia. A new review of 65 publications, reported in the journal GeroScience in 2026, looked at whether nucleotides, the building blocks of DNA and energy molecules, could help. According to research reviewed by Gram, laboratory and animal studies suggest these compounds may slow muscle loss and support muscle repair. Human studies are fewer and their results are mixed. The researchers concluded that nucleotides are a promising but experimental approach. Supplements such as NMN and NR should not be treated as interchangeable, and they are not yet recommended as routine treatment for sarcopenia.

Key Statistics

A 2026 structured review of 65 publications in GeroScience concluded that nucleotides remain a promising but experimental strategy for sarcopenia, with evidence coming mainly from cell studies, animal studies, and several human trials.

In a 2026 review published in GeroScience, researchers screened 1,763 unique records from three major databases and retained 65 publications, while noting that NAD+ precursor evidence is considerably more extensive but clinically heterogeneous.

The Quick Take

  • What they studied: Can nucleotides, which are natural building blocks in food and cells, and related compounds called NAD+ precursors help prevent or slow the muscle loss that comes with aging?
  • Who participated: This was a review of existing research rather than a study with its own volunteers. The authors searched three major research databases, screened 1,763 unique records, and included 65 publications covering cell studies, animal studies, and human trials.
  • Key finding: Cell and animal studies suggest that nucleotides may reduce muscle wasting and support muscle repair. Evidence for NAD+ precursors, such as NMN and NR, is larger but gives inconsistent results across clinical studies.
  • What it means for you: Nucleotides are not yet a proven treatment for age-related muscle loss. Strength training, adequate protein intake, and talking with a doctor remain the best-supported steps for older adults concerned about muscle health.

The Research Details

The researchers conducted a structured literature review, which means they followed a set of organized steps to find and evaluate existing studies. They used guidelines from PRISMA 2020, a widely used standard for reporting how research reviews are done. This standard helps make the review transparent and repeatable.

The team searched PubMed, Scopus, and the Web of Science, three large collections of scientific articles. They found 3,090 records in total. After removing 1,327 duplicates, they reviewed 1,763 unique records and read 159 in full. They kept 62 publications and added 3 more clinical reports found during revision, bringing the final total to 65.

The review compared three types of evidence: laboratory cell studies, animal studies, and human trials. It looked at conventional nucleotides, nucleoproteins, which are proteins bonded to nucleic acids, and compounds linked to NAD+, a molecule involved in how cells produce energy. The authors then summarized what the evidence showed rather than combining the results into a single statistical number.

A structured review is useful because it gathers the full range of available evidence in one place, rather than relying on a single study. By following set search rules and screening steps, the authors reduced the chance that they picked only studies that supported a particular idea. This approach gives readers a clearer view of what is known and what remains uncertain.

The review followed a recognized reporting standard, searched several major databases, and removed duplicate records. These steps make the findings more trustworthy. However, reviews are only as strong as the studies they include. Many of the included studies were small, involved cells or animals, or varied widely in design, which limits how confidently the results can be applied to people. The publication also appeared in a peer-reviewed journal, meaning other experts checked it before publication.

What the Results Show

The strongest early evidence for nucleotides comes from laboratory cell experiments and animal studies. In these settings, nucleotides appeared to help limit muscle shrinkage, which scientists call atrophy, and to support myogenesis, the process by which new muscle fibers form. These results are encouraging, but cells and animals do not always respond to a supplement the same way people do.

Several human intervention studies were also included. The review reports that these studies point to possible benefits, including attenuated muscle loss and improvements in some measures of physical function. The word “possible” matters here. The human trials were limited in number and size, so the authors describe the findings as potential rather than proven.

Evidence for NAD+ precursors, including NMN and NR, is much larger in volume. Even so, the clinical results are inconsistent. Some studies report benefits for certain outcomes, while others do not. This variation makes it difficult to draw a firm conclusion about whether these compounds help muscles in older adults.

The authors’ most important message is that the different compounds should not be grouped together. Mixtures of AMP, CMP, GMP, and UMP, nucleoproteins, NMN, and NR are distinct interventions with different evidence bases. The review states that current evidence does not justify recommending them for routine use in treating sarcopenia.

The review notes that nucleotides are involved in energy metabolism and in how cells respond to stress. These roles may explain why researchers are interested in them for muscle health. However, a biological role in the body does not automatically mean that taking extra nucleotides in supplement form will produce a measurable benefit.

The authors also highlight the growing interest in nutrition for older adults. As more research focuses on this group, scientists are looking for dietary strategies that could complement exercise and protein intake. The review suggests that nucleotides belong in this conversation, but they should be considered a research area rather than an established solution.

Muscle loss with age is well documented, and resistance exercise and adequate protein intake are established ways to address it. Nucleotides and NAD+ precursors have drawn attention because they play roles in cell energy and repair. This review fits with a broader pattern in aging research: laboratory and animal findings often generate excitement that is not always matched by consistent human results. The authors’ conclusion that nucleotides remain experimental is consistent with the cautious position taken in most current nutrition science on this topic.

The most important limitation is that this is a review, not a new clinical trial. The authors summarized existing studies, which vary in design, size, dosage, and the people studied. Because of this variation, the review did not calculate one combined result. Readers cannot tell exactly how large any benefit might be.

Many of the most direct findings come from cells and animals. Results in these models do not always translate to humans, especially older adults with different health conditions and diets.

The human evidence for NAD+ precursors is inconsistent, and the review does not resolve why different studies reached different conclusions. Finally, the review does not provide a specific recommended dose or safe long-term intake for any nucleotide supplement.

The Bottom Line

Confidence in nucleotides as a treatment for sarcopenia is currently low to moderate. The research supports further study, but it does not support using them as a routine treatment. Confidence is somewhat higher for the basic point that the compounds should not be treated as interchangeable, since the authors reached that conclusion across the evidence. Proven steps for muscle health, such as resistance training and adequate protein, carry much stronger evidence and should remain the priority. Anyone considering a supplement should discuss it with a healthcare provider first.

Older adults who are worried about muscle loss, caregivers, researchers, and nutrition professionals may find this review useful. People who already have a medical condition, take medications, or have kidney problems should talk with a doctor before starting any supplement. Younger adults with no concerns about muscle loss do not need to act on these findings. Anyone looking for a quick fix for muscle weakness should understand that the evidence does not support one yet.

Because nucleotides remain experimental, there is no established timeline for benefits. Any effects seen in future human trials would likely take weeks to months of consistent use to measure, and would need to be compared against a control group. Strength training and protein intake can produce measurable changes in muscle strength over several weeks, so these remain more practical starting points while research continues.

Frequently Asked Questions

Do nucleotide supplements help with muscle loss as you age?

Current evidence is early and experimental. A 2026 review of 65 publications found that cell and animal studies suggest possible muscle protection, but human results are limited and inconsistent. Nucleotides are not yet recommended as a routine treatment for age-related muscle loss.

Sarcopenia is the progressive loss of muscle mass, strength, and function that occurs with aging. Nutrition plays a role because adequate protein and overall diet support muscle maintenance. Resistance exercise combined with adequate protein is currently the most established approach, according to research reviewed by Gram.

Is NMN the same as NR for supporting muscles?

No, NMN and NR are different compounds and should not be treated as interchangeable. Both relate to NAD+ metabolism, but a 2026 review found their clinical results are heterogeneous, meaning studies report different outcomes. More research is needed before either is recommended for sarcopenia.

What should I do now to protect my muscle health as I get older?

Regular strength training and adequate daily protein are the best-supported steps for maintaining muscle. Staying physically active and discussing concerns with a healthcare provider can also help. Nucleotide supplements remain experimental, so check with a doctor before starting any new supplement.

Want to Apply This Research?

  • Track a simple, measurable marker of muscle strength, such as how many chair stands you can complete in 30 seconds, along with daily protein grams. Record your results weekly so you can see trends over time.
  • Use the app to set a daily protein goal and to log at least two strength sessions each week. If you are considering a nucleotide or NMN supplement, log it separately and note that the evidence is still experimental, then discuss it with your doctor before starting.
  • Review your strength and protein logs monthly and note any changes in energy, mobility, or daily tasks. Schedule a yearly check-in with a healthcare provider to review muscle health and any supplements you take. Update your approach as new human research on nucleotides becomes available.

This article summarizes a review of existing research on nucleotides and muscle loss in aging. The review does not establish that nucleotide or NAD+ precursor supplements are safe or effective for treating sarcopenia. This information is for general education only and is not medical advice. Please consult a qualified healthcare provider before starting, stopping, or changing any supplement, especially if you have a medical condition, take medications, or are pregnant or nursing.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Dietary nucleotides and NAD+  precursors in age-related sarcopenia. , GeroScience (2026). PubMed 43040062 | DOI
Topics
sarcopenia dietary nucleotides NAD+ precursors NMN muscle loss aging muscle health older adults nutrition and aging GeroScience review